Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hyponatremic coma under oxcarbazepine therapy.

B J Steinhoff1, K D Stoll, S R Stodieck

  • 1Neurologische Klinik, Ludwig-Maximilians-Universität München, Germany.

Epilepsy Research
|March 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alterations of intracerebral connectivity in epilepsy patients with secondary bilateral synchrony.

Epilepsy research·2020
Same author

MMW Fortschritte der Medizin·2019
Same author

Adjunctive perampanel for partial-onset seizures.

Acta neurologica Scandinavica·2018
Same author

Bilateral cingulum fiber reductions in temporal lobe epilepsy with unilateral hippocampal sclerosis.

European journal of radiology·2017
Same author

The role of presurgical EEG parameters and of reoperation for seizure outcome in temporal lobe epilepsy.

Seizure·2017
Same author

Pure endoscopic management of epileptogenic hypothalamic hamartomas.

Neurosurgical review·2017

Oxcarbazepine (OXC), a new antiepileptic drug, may cause severe hyponatremia, leading to coma. This case highlights the risk of serious adverse effects, even with improved tolerability over carbamazepine.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Oxcarbazepine (OXC) is an antiepileptic drug with comparable efficacy to carbamazepine (CBZ).
  • OXC is generally considered to have better tolerability than CBZ.
  • A potential adverse effect of OXC is hyponatremia, possibly occurring more frequently than with CBZ.

Observation:

  • This report details a patient who experienced hyponatremic coma.
  • The patient's serum sodium level was critically low at 115 mmol/l.
  • This represents the second documented case of severe hyponatremia induced by OXC.

Findings:

  • Oxcarbazepine can induce severe hyponatremia.
  • Hyponatremia associated with OXC can lead to serious clinical consequences such as coma.
  • The risk of hyponatremia with OXC warrants careful monitoring.

Related Experiment Videos

Implications:

  • Clinicians should be vigilant for hyponatremia in patients treated with oxcarbazepine.
  • Early detection and management of hyponatremia are crucial to prevent severe outcomes.
  • Further research may be needed to understand the mechanisms and incidence of OXC-induced hyponatremia.